The small drug firms set to benefit from RSV vaccines

Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK.

Chances are RSV, or respiratory syncytial virus, which has symptoms similar to the common cold.

It is a highly contagious disease that affects people of all ages, but can be especially dangerous for the elderly.

AIM-listed Synairgen is developing a broad treatment that could potentially fight both flu and RSV Poolbeg Pharma has identified and developed a preclinical agent using artificial intelligence – a world first.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.

Read the full article

Click to view all articles for the EPIC: HVO, POLB
Or click to view the full company profile:
Poolbeg Pharma plc

The history of the Flu Vaccine from 1940 to 2030

23rd March 2023

In 1918, about 50 million people, or one-fifth of the world’s population, became infected with the virus known as the “Spanish” flu, according to the Centers for Disease Control and Prevention (CDC). “The 1918 Pandemic was the reason the military was

Poolbeg Pharma granted US patent for treatment of inflammatory conditions

20th March 2023

Poolbeg Pharma, an infectious disease firm spun out from Irish vaccine research company Open Orphan, has been granted a patent by the US Patent and Trademark Office (USPTO). The US patent is related to methods introduced by Poolbeg

Can asthma sufferers exercise?

20th March 2023

Asthma sufferers will often avoid exercise, fearing that it will worsen their condition or induce an asthma attack. Whilst it can be the case that exercise triggers symptoms, this should not be a reason for it to be

hVIVO Omicron human challenge agent has been successfully manufactured

16th March 2023

hVIVO plc (LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that its Omicron human challenge agent has

Where is Influenza most commonly found in the world?

13th March 2023

Influenza isn’t just limited to certain areas of the world. The flu virus leads to nearly 40 million flu-related illnesses each year even though it is one of the most preventable diseases. It can be found in Asia and

Poolbeg Pharma granted US patent related to influenza drug

13th March 2023

Poolbeg Pharma has been granted a patent in the United States for the treatment of hypercytokinaemia using its new influenza drug POLB 001. The US patent covers the use of POLB 001 and related p38 MAP kinase inhibitors

EMA’s updated guideline to include broader coverage on Human Challenge Trials

10th March 2023

The European Medicines Agency (EMA) published an updated Guideline on clinical evaluation of vaccines (EMEA/ CHMP/VWP/164653/05 Rev. 1). This guideline was updated following EMA` s experience in the past decade with new vaccines applications, including the approval of

Poolbeg Pharma releases positive data from influenza trial

10th March 2023

Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections. POLB 001 showed success in reducing multiple markers

UK CRO hVIVO second Asia Pacific client in 2023

8th March 2023

hVIVO has signed a new testing contract with an Asia-Pacific based drug maker, which it says is an indication of its growing regional client base. The UK contract research organisation (CRO) shared minimal details of the £6.8 million

Poolbeg Pharma granted patent by USPTO for POLB 001

8th March 2023

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia

Positive results from Poolbeg Pharma’s human challenge trial

6th March 2023

Poolbeg Pharma – a company focused on developing infectious disease therapies – has announced data from its bacterial lipopolysaccharide (LPS) human challenge trial for POLB 001. The treatment is a viral strain agnostic, small molecule immunomodulator which is

Poolbeg Pharma receives positive results from POLB 001 LPS Human Challenge Trial

2nd March 2023

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF’), a leading infectious disease focused biopharmaceutical company, has announced the data readout from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to

Poolbeg Pharma & OneThree Biotech: Collaboration and themes in AI

28th February 2023

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.

10 Features of the ATMPs development

28th February 2023

There are several distinctive features that must be considered in the ATMP development: ATMPs are mainly for the unmet medical needs = severe, rare, or chronic diseases with no adequate conventional treatments. Risk-based approach = Dominant strategy of

SLAS2023: We have the building blocks, onto the building

24th February 2023

In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine, to how Brexit has changed the world’s relationship

Infinite possibilities for drug development

21st February 2023

Over 25 years Venn Life Sciences have built up substantial therapeutic and study experience, contributing to the efficient management of sites, budgets and communication channels. Venn is renowned for its hands-on approach and consistent delivery of high quality

Poolbeg Pharma Investment Case

20th February 2023

Poolbeg Pharma (LON:POLB / OTCQB:POLBF) Investment Case with CEO Jeremy Skillington. Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a unique capital light model. The company is focus on targeting the significant global medical need to treat

AI continues to gain momentum in the biopharmaceutical industry in 2023

17th February 2023

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

No more posts to show

Be sure to check our sister interview main ratings news website